RYTM250117P65000
- 0.00
- 0.000.00%
Rhythm Pharmaceuticals Newsroom
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $72
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Raises Target Price to $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Rhythm Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65
Jefferies Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $80
Jefferies Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $80
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
Oppenheimer Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $76
Rhythm Pharmaceuticals Initiated at Outperform by Oppenheimer
Rhythm Pharmaceuticals Price Target Announced at $76.00/Share by Oppenheimer
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $66
Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Rhythm Pharmaceuticals Price Target Raised to $66.00/Share From $59.00 by Goldman Sachs
Rhythm Pharmaceuticals Analyst Ratings